| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
261.92(M) |
| Last
Volume: |
1,607,087 |
Avg
Vol: |
2,316,426 |
| 52
Week Range: |
$0.449 - $1.67 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
36,653 |
73,355 |
186,690 |
544,022 |
| Total Sell Value |
$24,924 |
$42,909 |
$121,964 |
$1,484,432 |
| Total People Sold |
3 |
3 |
6 |
11 |
| Total Sell Transactions |
3 |
6 |
15 |
39 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Myriam Curet |
Director |
– • – |
2020-12-15 |
4 |
AS |
$17.82 |
$27,799 |
D/D |
(1,560) |
19,240 |
|
9% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2020-11-23 |
4 |
AS |
$16.40 |
$268,632 |
D/D |
(16,380) |
250,317 |
|
23% |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2020-11-16 |
4 |
S |
$16.93 |
$26,055 |
D/D |
(1,539) |
49,850 |
|
-15% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2020-11-16 |
4 |
S |
$16.93 |
$202,754 |
D/D |
(11,976) |
159,757 |
|
-15% |
|
| Robin Howard W |
President & CEO |
• • – |
2020-11-16 |
4 |
S |
$16.93 |
$202,737 |
D/D |
(11,975) |
352,043 |
|
-15% |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2020-11-16 |
4 |
S |
$16.93 |
$140,113 |
D/D |
(8,276) |
226,973 |
|
-15% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2020-11-16 |
4 |
S |
$16.93 |
$501,433 |
D/D |
(29,618) |
266,697 |
|
-15% |
|
| Ajer Jeffrey Robert |
Director |
– • – |
2020-09-28 |
4 |
AS |
$17.25 |
$56,063 |
D/D |
(3,250) |
25,975 |
|
34% |
|
| Chess Robert |
Director |
– • – |
2020-09-25 |
4 |
AS |
$17.75 |
$97,625 |
D/D |
(5,500) |
280,573 |
|
19% |
|
| Whitfield Roy A |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,100 |
237,350 |
|
- |
|
| Ajer Jeffrey Robert |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,100 |
29,225 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,100 |
185,674 |
|
- |
|
| Chess Robert |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,100 |
286,073 |
|
- |
|
| Myriam Curet |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,100 |
20,800 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,100 |
35,800 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,100 |
24,100 |
|
- |
|
| Ajer Jeffrey Robert |
Director |
– • – |
2020-09-21 |
4 |
AS |
$19.74 |
$44,415 |
D/D |
(2,250) |
20,125 |
|
1% |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2020-09-17 |
4 |
AS |
$19.96 |
$39,920 |
D/D |
(2,000) |
235,249 |
|
-3% |
|
| Chess Robert |
Director |
– • – |
2020-09-08 |
4 |
AS |
$18.53 |
$148,240 |
D/D |
(8,000) |
276,973 |
|
-8% |
|
| Chess Robert |
Director |
– • – |
2020-09-08 |
4 |
OE |
$9.24 |
$73,920 |
D/D |
8,000 |
284,973 |
|
- |
|
| Whitfield Roy A |
Director |
– • – |
2020-09-04 |
4 |
OE |
$9.24 |
$277,200 |
D/D |
30,000 |
228,250 |
|
- |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2020-08-18 |
4 |
AS |
$19.68 |
$39,360 |
D/D |
(2,000) |
237,249 |
|
-8% |
|
| Robin Howard W |
President & CEO |
• • – |
2020-08-17 |
4 |
S |
$19.67 |
$233,778 |
D/D |
(11,885) |
364,018 |
|
7% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2020-08-17 |
4 |
S |
$19.67 |
$515,354 |
D/D |
(26,200) |
296,315 |
|
7% |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2020-08-17 |
4 |
AS |
$19.67 |
$122,839 |
D/D |
(6,245) |
239,249 |
|
-7% |
|
909 Records found
|
|
Page 7 of 37 |
|
|
0.14 (10.61%) 
